Trexquant Investment LP Decreases Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Trexquant Investment LP trimmed its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 43.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 494,356 shares of the biotechnology company's stock after selling 386,635 shares during the quarter. Trexquant Investment LP owned approximately 0.24% of BioCryst Pharmaceuticals worth $3,718,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Schroder Investment Management Group grew its stake in shares of BioCryst Pharmaceuticals by 523.9% during the 4th quarter. Schroder Investment Management Group now owns 522,657 shares of the biotechnology company's stock worth $3,936,000 after acquiring an additional 438,887 shares during the period. Pictet Asset Management Holding SA lifted its holdings in BioCryst Pharmaceuticals by 34.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 26,442 shares of the biotechnology company's stock valued at $199,000 after purchasing an additional 6,840 shares during the last quarter. Norges Bank bought a new position in BioCryst Pharmaceuticals during the fourth quarter worth about $3,947,000. Prudential Financial Inc. increased its stake in shares of BioCryst Pharmaceuticals by 10.2% in the fourth quarter. Prudential Financial Inc. now owns 983,033 shares of the biotechnology company's stock worth $7,392,000 after purchasing an additional 90,603 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after purchasing an additional 1,583,826 shares during the period. 85.88% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on BCRX. Wedbush initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price objective for the company. Evercore ISI increased their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Needham & Company LLC reissued a "buy" rating and issued a $15.00 price target on shares of BioCryst Pharmaceuticals in a report on Thursday. Finally, JMP Securities restated a "market outperform" rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $15.57.

BioCryst Pharmaceuticals Trading Up 6.4 %

Shares of NASDAQ BCRX traded up $0.41 during midday trading on Friday, hitting $6.82. 3,113,466 shares of the company's stock were exchanged, compared to its average volume of 2,805,137. The business's fifty day moving average price is $7.96 and its two-hundred day moving average price is $7.74. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -11.18 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. BioCryst Pharmaceuticals's revenue was up 40.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.28 EPS. Equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.